Gas chromatographic/mass spectrometric differentiation of atenolol, metoprolol, propranolol, and an interfering metabolite product of metoprolol : final report / Mike K. Angier ... [et al.].
| Other author | Angier, Mike K. |
| Other author | United States. Office of Aerospace Medicine. |
| Format | Electronic |
| Publication Info | Washington, DC : Office of Aerospace Medicine, U.S. Dept. of Transportation, Federal Aviation Administration ; Springfield, Va. : National Technical Information Service [distributor], [2004] |
| Description | i, 6 p. : digital, PDF file |
| Supplemental Content | https://purl.fdlp.gov/GPO/LPS105686 |
| Subjects |
| Abstract | Pilots who are considered hypertensive are closely monitored by the Federal Aviation Administration (FAA) to ensure that their hypertension is properly controlled. During the investigation of fatal civil aviation accidents, postmortem samples obtained from pilots are submitted to the FAA's Civil Aerospace Medical Institute (CAMI) for toxicological evaluation. During such evaluation, submitted samples are analyzed for prescription and nonprescription drugs, and it is common to find beta-blocker antihypertensives such as atenolol, metoprolol, and propranolol in the submitted biological samples. During a 10-year period of 1993-2002, postmortem samples from 3290 civil aviation accident pilot fatalities (cases) were received by CAMI. Toxicological evaluation of these cases revealed that 50 of the 3290 fatalities had the commonly prescribed beta-blockers, atenolol, metoprolol, and propranolol. Out of the 50 fatalities, atenolol, metoprolol, and propranolol were found to be present in 24, 19, and 7 fatalities, respectively, but the initial analysis indicated the presence of atenolol and metoprolol in 4 of these pilot fatalities. Since (i) the combined use of both drugs was not consistent with the history of the drug use by those pilots, (ii) it is uncommon to simultaneously prescribe 2 beta-blockers, and (iii) these commonly used antihypertensives have considerable amount of chemical and structural similarity (6), further examination was undertaken for those fatality cases wherein atenolol and metoprolol were initially detected. Such examination entailed selectively and simultaneously analyzing the 3 commonly used beta-blockers in the submitted biological samples and rectifying any possible analytical interference with the antihypertensives. |
| General note | Title from title screen (viewed on Nov. 20, 2008). |
| General note | "October 2004." |
| General note | "DOT/FAA/AM-04/15." |
| General note | GPO Cataloging Record Distribution Program (CRDP). |
| Bibliography note | Includes bibliographical references. |
| Funding information | AM-B-04-TOX-204 |
| Technical details | Mode of access: Internet from the FAA web site. Address as of 11/20/08: http://www.faa.gov/library/reports/medical/oamtechreports/2000s/media/0415.pdf; current access available via PURL. |
| Issued in other form | Gas chromatographic/mass spectrometric differentiation of atenolol, metoprolol, propranolol, and an interfering metabolite product of metoprolol i, 6 p. |
| Issued in other form | Gas chromatographic/mass spectrometric differentiation of atenolol, metoprolol, propranolol, and an interfering metabolite product of metoprolol i, 6 p. |
| Technical rpt number | DOT/FAA/AM-04/15 |
| GPO item number | 0431-E-04 (online) |
| Govt. docs number | TD 4.210:04/15 |
Availability
| Library | Location | Call Number | Status | Item Actions |
|---|---|---|---|---|
| Electronic Resources | Access Content Online | ✔ Available |